Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.
Kalinsky K, Chi D, Lee S, Adelson K, Crew K, Chuang E, Makower D, Hershman D, Califano A, Silva J, Maurer M. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer. Journal Of Clinical Oncology 2014, 32: tps666-tps666. DOI: 10.1200/jco.2014.32.15_suppl.tps666.Peer-Reviewed Original ResearchMetastatic HER2-positive breast cancerPhase I/II trialHER2-positive breast cancerII trialBreast cancerTrastuzumabRuxolitinibCancerTrials